HighTower Advisors’s Lineage Cell Therapeutics LCTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $52.4K | Hold |
57,706
| – | – | ﹤0.01% | 3499 |
|
|
2025
Q1 | $26.1K | Hold |
57,706
| – | – | ﹤0.01% | 3448 |
|
|
2024
Q4 | $29K | Buy |
57,706
+19,100
| +49% | +$9.6K | ﹤0.01% | 3432 |
|
|
2024
Q3 | $35K | Sell |
38,606
-17,065
| -31% | -$15.5K | ﹤0.01% | 3393 |
|
|
2024
Q2 | $56K | Sell |
55,671
-8,300
| -13% | -$8.35K | ﹤0.01% | 3247 |
|
|
2024
Q1 | $95K | Buy |
63,971
+9,900
| +18% | +$14.7K | ﹤0.01% | 3128 |
|
|
2023
Q4 | $59K | Hold |
54,071
| – | – | ﹤0.01% | 3221 |
|
|
2023
Q3 | $64K | Buy |
54,071
+19,955
| +58% | +$23.6K | ﹤0.01% | 3147 |
|
|
2023
Q2 | $48K | Sell |
34,116
-16,000
| -32% | -$22.5K | ﹤0.01% | 3123 |
|
|
2023
Q1 | $75K | Buy |
50,116
+16,000
| +47% | +$23.9K | ﹤0.01% | 2953 |
|
|
2022
Q4 | $40K | Buy |
34,116
+700
| +2% | +$821 | ﹤0.01% | 3005 |
|
|
2022
Q3 | $37K | Hold |
33,416
| – | – | ﹤0.01% | 2865 |
|
|
2022
Q2 | $53K | Hold |
33,416
| – | – | ﹤0.01% | 2856 |
|
|
2022
Q1 | $51K | Hold |
33,416
| – | – | ﹤0.01% | 3009 |
|
|
2021
Q4 | $82K | Buy |
33,416
+100
| +0.3% | +$245 | ﹤0.01% | 2912 |
|
|
2021
Q3 | $84K | Buy |
33,316
+17,000
| +104% | +$42.9K | ﹤0.01% | 2840 |
|
|
2021
Q2 | $46K | Hold |
16,316
| – | – | ﹤0.01% | 2849 |
|
|
2021
Q1 | $38K | Hold |
16,316
| – | – | ﹤0.01% | 2793 |
|
|
2020
Q4 | $28K | Buy |
+16,316
| New | +$28K | ﹤0.01% | 2354 |
|